GlassScriptPhysician profile
Hussein Christopher Khraizat
NPI 1932588381
$3,899.25
in general payments reported to CMS, 2019-2025
29 companies · $596 in 2025
The $596 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $270 · 2020: $243 · 2021: $546 · 2022: $786 · 2023: $724 · 2024: $734 · 2025: $596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,054.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,053.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $851.20 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $412.90 | 2021-2025 | |
| Amgen INC. | $406.27 | 2019-2024 | Repatha, Prolia, Evenity |
| Pfizer INC. | $348.63 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $233.30 | 2021-2022 | |
| Lilly USA, LLC | $232.43 | 2020-2025 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $208.05 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $165.58 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $163.02 | 2019-2025 | Breztri, Airsupra |
| Abbott Laboratories | $143.04 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Dexcom, INC. | $89.43 | 2022-2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $77.81 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $72.09 | 2019-2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.05 | 2022-2025 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $58.70 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $58.08 | 2024-2025 | Symbravo, Auvelity |
| Amarin Pharma, INC. | $51.23 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $37.02 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $33.22 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $29.75 | 2022-2024 | Gardasil 9, Capvaxive, Gardasil |
| Sumitomo Pharma America, INC. | $22.60 | 2025 | Gemtesa |
| Tolmar, INC. | $21.21 | 2024 | |
| Agios Pharmaceuticals, INC. | $20.35 | 2025 | Pyrukynd |
| E.R. Squibb & Sons, L.L.C. | $19.28 | 2021 | |
| Esperion Therapeutics, INC. | $19.09 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.96 | 2022 | |
| Shield Therapeutics INC | $16.76 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.41 | 2025 | Caplyta |
| Ardelyx, INC. | $15.79 | 2025 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hussein Khraizat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.